Bioasis Technologies Inc. a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of central nervous system (CNS) disorders, appoints John E. Curran, CPA and David M. Wurzer, CPA to the Bioasis Board of Directors, filling two of the current vacancies on the board. Director Maha Radhakrishnan, M.D. has resigned due to personal reasons, effective immediately.
“We are very happy to welcome Dave and John to our board. They bring significant financial, board and audit and compensation committee expertise and their acceptance of these appointments supports the Company’s strategic business plans. Bioasis will benefit from their business acumen and counsel as the management team works to advance the Company with guidance from the board,” says Dr. Deborah Rathjen, chair of the board. “We would also like to thank Dr. Maha Radhakrishnan for her service and contributions to the board and wish her the very best.”
Since the changes to the board, the composition of the board committees has been revised as follows:
- Audit Committee (fully comprised of independent directors): Mr. John E. Curran, CPA (chair), Dr. Deborah Rathjen and Mr. David M. Wurzer, CPA
- Compensation Committee (fully comprised of independent directors): Dr. Nancy Stagliano, Dr. Deborah Rathjen and Mr. David M. Wurzer, CPA
“John and Dave have uncompromised standards for corporate governance and have displayed brilliant financial, operational and business leadership skills and exceptional values throughout their careers,” says Mark Day, Ph.D., director and president and chief executive officer. “We are thrilled to have them on our board and look forward to working with them.”
John Curran is a former partner at Deloitte & Touche LLP in Hartford, Conn., United States. He recently retired after spending 41 years with Deloitte. Curran has substantial experience advising and supporting business strategic development and implementation, including growth strategies (organic and merger & acquisition), marketplace strategies, capital structuring (equity and debt structuring) as well as managing business performance, profitability and creating shareholder value. He has served as a lead advisor and provided oversight on more than 50 due diligence projects. He has advised and supported extensive capital structuring and financing transactions, including initial and ongoing public offerings and private placements of debt and equity securities. Curran has broad U.S. Securities and Exchange Commission (SEC) experience, including registration and financial statement filings. He has also advised on and supported issue resolution including, responding to SEC comment letters, developing accounting and financial disclosures and compliance with SEC rules and regulations.
Dave Wurzer joined Connecticut Innovations (CI), the state of Connecticut’s “venture capital arm,” in 2009 where he currently serves as executive vice president and chief investment officer. Wurzer is responsible for managing the investment function at CI, which includes planning and performance measurement for the $125 million venture capital portfolio, comprised of investments in over 150 Connecticut technology companies. Throughout his 38-year career, Wurzer has accumulated noteworthy experience in identifying, evaluating and assisting early-stage companies across a broad range of industries with funding through equity and equity-related (venture) investments to help spur growth. He has made meaningful contributions reviewing business strategies and raising capital for the companies and has also been involved in negotiating strategic and business development alliances with several pharmaceutical and biotech companies.